Colgate-Palmolive Company (NYSE: CL) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide a clear set of Q4-only financial results. Unless otherwise noted, dollar amounts are in millions.
Business context
Colgate-Palmolive sells consumer oral, personal and home care products and Hill’s Pet Nutrition products in more than 200 countries and territories. About two-thirds of sales came from outside the U.S. in 2022. Oral, Personal and Home Care generated $14,254 of sales; Pet Nutrition generated $3,713.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net sales | $17,967 | $17,421 | +3.0% |
| Organic sales growth (non-GAAP) | 7.0% | 4.5% | +2.5 percentage points |
| Gross profit margin | 57.0% | 59.6% | -260 bps |
| Operating profit (GAAP) | $2,893 | $3,332 | -13% |
| Operating profit margin (GAAP) | 16.1% | 19.1% | -300 bps |
| Net income attributable to Colgate | $1,785 | $2,166 | -18% |
| Diluted EPS | $2.13 | $2.55 | -16% |
| Operating cash flow | $2,556 | $3,325 | -23% |
| Capital expenditures | $696 | $567 | +$129 |
| Total debt at year-end | $8,766 | $7,245 | +$1,521 |
Sales growth reflected 9.5% higher net selling prices, offset by 2.0% lower volume and 4.5% unfavorable foreign exchange; acquisitions contributed 0.5% to volume. Cost inflation weighed heavily on profitability: higher raw and packaging costs reduced gross margin by 810 bps, partly offset by pricing (+360 bps) and cost savings (+220 bps). Adjusted, non-GAAP operating profit was $3,681, down 5%; adjusted diluted EPS was $2.97, down 7%.
Hill’s Pet Nutrition sales grew 12% to $3,713, with 13% organic growth, while segment operating profit fell 6% to $850 and its margin declined 430 bps to 22.9%. Oral, Personal and Home Care sales increased 1% to $14,254, with 5.5% organic growth.
Liquidity, debt and capital allocation
Cash and cash equivalents were $775 at year-end, versus $832 a year earlier. Operating cash flow declined primarily due to lower net income and working-capital use, including higher inventories and receivables and lower payables and accruals. The company reported $3,401 of unused domestic and foreign credit lines and a $3,000 revolving credit facility expiring in November 2027. Management expects operating cash flow and debt issuance to cover foreseeable operating and recurring cash needs.
Long-term debt, including its current portion, was $8,755 at year-end. Commercial paper outstanding was $1,778. The company paid $1,691 in dividends and repurchased $1,308 of shares during 2022; the board authorized a new repurchase program of up to $5 billion. Capital expenditures for 2023 were expected to be approximately 4% of sales.
Material changes, outlook and risks
- Filorga impairment: The company recorded a $721 pretax ($620 after-tax) non-cash impairment in Q4 2022, including $332 of goodwill and $389 of intangible assets. The filing cites continuing pandemic-related disruption, particularly in China and travel retail, and higher interest rates. A further impairment could arise if forecasts or valuation assumptions weaken.
- Acquisitions and restructuring: Colgate acquired U.S. pet-food manufacturing operations from Red Collar for a final $719 purchase price and also acquired an Italian pet-food plant. Its 2022 Global Productivity Initiative incurred $110 pretax charges in 2022; total expected charges are $200–$240 pretax through implementation, substantially complete by mid-2024, with projected annualized pretax savings of $90–$110.
- Management outlook: Management expected the difficult raw-material, packaging and logistics cost environment to continue in 2023 and planned further pricing actions. It cautioned that pricing, inflation and higher interest rates could reduce consumer demand, volumes or product mix. It did not provide a clear quantified 2023 sales or EPS forecast in the supplied text.
- Geopolitical and operating exposure: The war in Ukraine, sanctions, currency volatility and supply-chain costs remain risks. Russia and Ukraine together were not separately quantified; Eurasia represented about 2% of consolidated sales and 3% of operating profit in 2022. COVID-19 impacts had largely abated but uncertainty remained, especially in China and travel retail.
- Contingencies and taxes: The company estimated reasonably possible legal losses above recorded accruals at $0–approximately $475, while noting ultimate outcomes could differ materially. Brazilian tax proceedings include assessments of approximately $119 and $52. An IRS matter for 2010–2018 was estimated at approximately $145 in tax and interest and was not included in uncertain tax positions; the company was reassessing its position.
Other key exposures include foreign exchange, commodity and freight costs, retailer bargaining power and inventory actions, competition and private-label substitution, supply-chain concentration, cybersecurity, regulation, climate and sustainability requirements, and the ability to execute innovation and cost-saving programs. The independent auditor issued an unqualified opinion on the financial statements and internal controls; the Filorga impairment assessment was identified as a critical audit matter.
Most important facts for investors to verify
- Whether pricing can offset cost inflation without materially weakening volumes, mix or market share.
- Hill’s margin recovery and the returns from the Red Collar and Nutriamo capacity acquisitions.
- Filorga performance and the sensitivity of its remaining goodwill and intangible values to growth and discount-rate assumptions.
- Cash generation, working-capital normalization, rising debt and the company’s continued capacity to fund dividends and repurchases.
- Actual restructuring charges, timing and savings compared with the initiative’s stated estimates.
- Developments in the disclosed legal and tax matters, particularly the Brazilian proceedings and IRS dispute.